Stoke Therapeutics (STOK) Shares Outstanding (Diluted Average) (2021 - 2026)

Stoke Therapeutics has reported Shares Outstanding (Diluted Average) for 6 years, with the latest figure at $63.1 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Diluted Average) rose 6.17% year-over-year to $63.1 million; the trailing twelve-month figure through Mar 2026 stood at $63.1 million (up 6.17% YoY), and the FY2025 full-year result was $59.2 million, up 9.65% from the prior year.
• Shares Outstanding (Diluted Average) for Q1 2026 stood at $63.1 million, up from $59.2 million in the prior quarter.
• The five-year high for Shares Outstanding (Diluted Average) was $63.1 million in Q1 2026, with the low at $37.4 million in Q1 2022.
• Average Shares Outstanding (Diluted Average) over 5 years is $49.2 million, with a median of $46.2 million recorded in 2024.
• Peak annual rise in Shares Outstanding (Diluted Average) reached 28.44% in 2025, while the deepest fall reached 4.03% in 2025.
• Tracing STOK's Shares Outstanding (Diluted Average) over 5 years: stood at $38.9 million in 2022, then rose by 13.1% to $44.0 million in 2023, then advanced by 22.76% to $54.0 million in 2024, then rose by 9.65% to $59.2 million in 2025, then rose by 6.49% to $63.1 million in 2026.
• The last three Shares Outstanding (Diluted Average) figures came in at $63.1 million (Q1 2026), $59.2 million (Q4 2025), and $58.6 million (Q3 2025), per Business Quant data.

Peer Comparison